Vlado Perkovic's Publications

Ohkuma T, Jun M, Chalmers J et alii
Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes

Journal articles
2019
Clinical Journal of the American Society of Nephrology
Li J, Badve SV, Zhou Z et alii
The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program

Journal articles
2019
DIABETES
Cooper ME, Perkovic V, Groop PH et alii
Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria

Journal articles
2019
Journal of hypertension
Figtree GA, Rådholm K, Barrett TD et alii
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Journal articles
2019
Circulation
Heerspink HJL, Parving HH, Andress DL et alii
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Journal articles
2019
The Lancet
Rahimi K, Canoy D, Nazarzadeh M et alii
Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: An overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)

Journal articles
2019
BMJ Open
Cheung AK, Chang TI, Cushman WC et alii
Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Journal articles
2019
Kidney International
Toyama T, Neuen BL, Jun M et alii
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis

Journal articles
2019
Diabetes
Liao JL, van den Broek-Best O, Smyth B et alii
Effect of extended hours dialysis on sleep quality in a randomized trial

Journal articles
2019
Nephrology
Thompson A, Carroll K, Inker LA et alii
Proteinuria reduction as a surrogate end point in trials of IgA nephropathy

Journal articles
2019
Clinical Journal of the American Society of Nephrology
Garg AX, Chan MTV, Cuerden MS et alii
Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: A randomized controlled trial

Journal articles
2019
CMAJ
Jun M, Jardine MJ, Perkovic V et alii
Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study

Journal articles
2019
PLoS ONE
Heerspink HJL, Greene T, Tighiouart H et alii
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Journal articles
2019
The Lancet Diabetes and Endocrinology
Zhou Z, Lindley RI, Rådholm K et alii
Canagliflozin and Stroke in Type 2 Diabetes Mellitus

Journal articles
2019
Stroke
Coresh J, Heerspink HJL, Sang Y et alii
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Journal articles
2019
The Lancet Diabetes and Endocrinology
Inker LA, Grams ME, Levey AS et alii
Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium

Journal articles
2019
American Journal of Kidney Diseases
McGuire DK, Alexander JH, Johansen OE et alii
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Journal articles
2019
Circulation
Bello AK, Levin A, Lunney M et alii
Status of care for end stage kidney disease in countries and regions worldwide: International cross sectional survey

Journal articles
2019
The BMJ
Ohkuma T, Van Gaal L, Shaw W et alii
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

Journal articles
2019
Diabetes
Inagaki N, Yang W, Watada H et alii
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

Journal articles
2019
Diabetology International
Neuen BL, Ohkuma T, Neal B et alii
Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program

Journal articles
2019
Journal of the American Society of Nephrology
Matthews DR, Li Q, Perkovic V et alii
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

Journal articles
2019
Diabetologia
Lioufas N, Toussaint ND, Pedagogos E et alii
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction on Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study

Journal articles
2019
BMJ Open
Smyth B, Krishnan AV, Gallagher M et alii
Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol

Journal articles
2019
BMJ Open
Ohkuma T, Jun M, Rodgers A et alii
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus

Journal articles
2019
Hypertension (Dallas
Rosenstock J, Perkovic V, Johansen OE et alii
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Journal articles
2019
JAMA - Journal of the American Medical Association

Previous Next

Vlado Perkovic's Publications

Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes

The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: An overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)

Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis

Effect of extended hours dialysis on sleep quality in a randomized trial

Proteinuria reduction as a surrogate end point in trials of IgA nephropathy

Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: A randomized controlled trial

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Canagliflozin and Stroke in Type 2 Diabetes Mellitus

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Status of care for end stage kidney disease in countries and regions worldwide: International cross sectional survey

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction on Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study

Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol

Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

The George Institute for Global Health

The George Institute country sites:

Affiliation/s

Acknowledgement of Country